CLL
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...
From the Journals
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...
From the Journals
Bendamustine/rituximab combo proves viable for comorbid CLL
Combination bendamustine and rituximab offers an effective treatment option for older, sicker patients with chronic lymphocytic leukemia.
From the Journals
Ibrutinib sustained responses in refractory CLL in long-term follow-up
Follow-up data from the RESONATE study suggests that long-term treatment with ibrutinib is effective and safe in patients with relapsed/refractory...
From the Journals
Venetoclax and obinutuzumab induces deep responses in CLL
The phase 1b, dose-escalation study is one of a few studies looking at the combination of venetoclax and obinutuzumab in chronic lymphocytic...
From the Journals
Short telomeres predict poorer response to chemo in CLL
High-throughput, single telomere–length analysis appears to be a useful tool in predicting response to FCR-based treatment among previously...
From the Journals
CLL, GVHD may raise risk for skin cancer after allo-HCT
The retrospective analysis identifies previously unknown risk factor for skin cancer associated with allogeneic hematopoietic cell transplantation...
From the Journals
Targeted triplet shows potential for B-cell cancers
The nonchemotherapy regimen achieved complete or partial responses in more than 80% of patients in the phase 1 study.
News
FDA approves ibrutinib plus obinutuzumab for CLL/SLL
The approval is supported by the phase 3 iLLUMINATE trial.
Conference Coverage
Uninterrupted ibrutinib with CAR T could improve CLL outcomes
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
From the Journals
Obinutuzumab-based regimens yield durable remissions in CLL
The findings suggest these new combinations may be more effective at clearing residual disease than rituximab-based therapy.